# Francois Eisinger

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 110 papers | 2,797 citations | 257101 24 h-index | 205818 48 g-index |
| 122 all docs | 122 docs citations | 122 times ranked | 3832 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948. | 2.6 | 257 |
| 2 | Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212. | 1.5 | 244 |
| 3 | Typical medullary breast carcinomas have a basal/myoepithelial phenotype. Journal of Pathology, 2005, 207, 260-268. | 2.1 | 198 |
| 4 | Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers. American Journal of Pathology, 2002, 161, 1223-1233. | 1.9 | 144 |
| 5 | Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. Lancet, The, 1999, 353, 919-920. | 6.3 | 136 |
| 6 | Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Human Molecular Genetics, 2002, 11, 863-872. | 1.4 | 117 |
| 7 | Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee. Annals of Oncology, 1998, 9, 939-950. | 0.6 | 116 |
| 8 | Disclosure to the family of breast/ovarian cancer genetic test results: Patient's willingness and associated factors. American Journal of Medical Genetics Part A, 2000, 94, 13-18. | 2.4 | 115 |
| 9 | Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene, 1997, 14, 339-347. | 2.6 | 60 |
| 10 | Testing for BRCA1 mutations: a cost-effectiveness analysis. European Journal of Human Genetics, 2002, 10, 599-606. | 1.4 | 58 |
| 11 | Histoprognostic grade in BRCA1-associated breast cancer. Lancet, The, 1995, 345, 1503. | 6.3 | 57 |
| 12 | Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. International Journal of Cancer, 2019, 144, 1962-1974. | 2.3 | 50 |
| 13 | Novel indications forBRCA1 screening using individual clinical and morphological features. , 1999, 84, 263-267. | | 47 |
| 14 | Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. European Journal of Human Genetics, 2000, 8, 204-208. | 1.4 | 43 |
| 15 | Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing. European Journal of Cancer, 2006, 42, 871-881. | 1.3 | 43 |
| 16 | Loss of heterozygosity at loci from chromosome arm 22Q in human sporadic breast carcinomas. , 1998, 75, 181-186. | | 38 |
| 17 | Evidence for a third breast-cancer susceptibility gene. Lancet, The, 1994, 344, 1151-1152. | 6.3 | 37 |
| 18 | Low frequency of lymph-node metastasis in BRCA1-associated breast cancer. Lancet, The, 1998, 351, 1633-1634. | 6.3 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Patientsâ€™ characteristics and rate of Internet use to obtain cancer information. Journal of Public Health, 2006, 28, 235-237. | 1.0 | 33 |
| 20 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747. | 1.4 | 32 |
| 21 | Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). Breast Cancer Research, 2012, 14, R99. | 2.2 | 32 |
| 22 | Full access to medical records does not modify anxiety in cancer patients. Cancer, 2011, 117, 4796-4804. | 2.0 | 28 |
| 23 | BRCA1and Medullary Breast Cancer. JAMA - Journal of the American Medical Association, 1998, 280, 1227. | 3.8 | 27 |
| 24 | IMPACT OF GENE PATENTS ON THE COST-EFFECTIVE DELIVERY OF CARE: THE CASE OF BRCA1 GENETIC TESTING. International Journal of Technology Assessment in Health Care, 2003, 19, 287-300. | 0.2 | 27 |
| 25 | Effects of genetic consultation on perception of a family risk of breast/ovarian cancer and determinants of inaccurate perception after the consultation. Journal of Clinical Epidemiology, 2002, 55, 665-675. | 2.4 | 24 |
| 26 | Fallopian Tube Cancer as a Feature of BRCA1-Associated Syndromes. Gynecologic Oncology, 2000, 78, 263-264. | 0.6 | 23 |
| 27 | Cancer screening in France: subjectsâ€™ and physiciansâ€™ attitudes. Cancer Causes and Control, 2008, 19, 431-434. | 0.8 | 23 |
| 28 | Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location inBRCA1/2Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 698-707. | 1.1 | 21 |
| 29 | Cancer genetic consultation and anxiety in healthy consultees. Psychology and Health, 1999, 14, 379-390. | 1.2 | 20 |
| 30 | Impact of organised programs on colorectal cancer screening. BMC Cancer, 2008, 8, 104. | 1.1 | 20 |
| 31 | Prophylactic mastectomy: ethical issues. British Medical Bulletin, 2007, 81-82, 7-19. | 2.7 | 19 |
| 32 | Telehealth applied to physical activity during cancer treatment: a feasibility, acceptability, and randomized pilot study. Supportive Care in Cancer, 2018, 26, 3413-3421. | 1.0 | 19 |
| 33 | Sociogeographical factors associated with participation in colorectal cancer screening. Gastroenterologie Clinique Et Biologique, 2010, 34, 534-540. | 0.9 | 18 |
| 34 | Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence. Current Oncology Reports, 2018, 20, 18. | 1.8 | 17 |
| 35 | Four Years Analysis of Cancer Genetic Clinics Activity in France from 1994 to 1997: A Survey on 801 Patients. Disease Markers, 1999, 15, 15-29. | 0.6 | 16 |
| 36 | Impact of general practitioners' sex and age on systematic recommendation for cancer screening. European Journal of Cancer Prevention, 2011, 20, S39-S41. | 0.6 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012. European Journal of Human Genetics, 2013, 21, 118-118. | 1.4 | 16 |
| 38 | Organized colorectal cancer screening programmes. European Journal of Cancer Prevention, 2011, 20, S26-S32. | 0.6 | 15 |
| 39 | p53 involvement in BRCA1-associated breast cancer. Lancet, The, 1997, 350, 1101. | 6.3 | 13 |
| 40 | Molecular study of the perforin gene in familial hematological malignancies. Hereditary Cancer in Clinical Practice, 2011, 9, 9. | 0.6 | 13 |
| 41 | Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 1082-1086. | 1.3 | 13 |
| 42 | GENESIS: a French national resource to study the missing heritability of breast cancer. BMC Cancer, 2016, 16, 13. | 1.1 | 13 |
| 43 | Current and Former Smokers: Who Wants To Be Screened?. Clinical Lung Cancer, 2018, 19, 493-501. | 1.1 | 13 |
| 44 | Histological type and syncytial growth pattern affect E-cadherin expression in a multifactorial analysis of a combined panel of sporadic andBRCA1-associated breast cancers. , 1999, 83, 45-49. | | 12 |
| 45 | Variation in prophylactic surgery decisions. Lancet, The, 2000, 356, 1687. | 6.3 | 12 |
| 46 | Re: Familial Multiple Myeloma: a Family Study and Review of the Literature. Journal of the National Cancer Institute, 2002, 94, 461-462. | 3.0 | 12 |
| 47 | Colorectal cancer screening program: cost effectiveness of systematic recall letters. Gastroenterologie Clinique Et Biologique, 2007, 31, 929-933. | 0.9 | 12 |
| 48 | Prediction of BRCA1 Germ-Line Mutation Status in Patients with Breast Cancer Using Histoprognosis Grade, MS110, Lys27H3, Vimentin, and KI67. Pathobiology, 2013, 80, 219-227. | 1.9 | 12 |
| 49 | Hereditary breast cancer, circa 1750. Lancet, The, 1998, 351, 1366. | 6.3 | 11 |
| 50 | Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys. Familial Cancer, 2001, 1, 157-162. | 0.9 | 11 |
| 51 | Gene-expression profiling and identification of patients at high risk of breast cancer. Lancet, The, 2002, 360, 173-174. | 6.3 | 11 |
| 52 | Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines. Genes Chromosomes and Cancer, 2002, 33, 217-224. | 1.5 | 11 |
| 53 | Familial hematological malignancies: ASXL1 gene investigation. Clinical and Translational Oncology, 2016, 18, 385-390. | 1.2 | 11 |
| 54 | Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, 2016, 7, 79428-79441. | 0.8 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2). European Journal of Human Genetics, 2010, 18, 1071-1071. | 1.4 | 10 |
| 56 | Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. Familial Cancer, 2016, 15, 497-506. | 0.9 | 10 |
| 57 | ARLTS1, potential candidate gene in familial aggregation of hematological malignancies. Bulletin Du Cancer, 2017, 104, 123-127. | 0.6 | 10 |
| 58 | Colon Cancer Screening Programs: Impact of an Organized Screening Strategy Assessed by the EDIFICE Surveys. Current Oncology Reports, 2018, 20, 16. | 1.8 | 10 |
| 59 | Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. , 1999, 85, 2291-2293. | | 9 |
| 60 | Breast cancer screening in women aged 50â€“74 years. European Journal of Cancer Prevention, 2011, 20, S8-S12. | 0.6 | 9 |
| 61 | Organized colorectal cancer screening programmes. European Journal of Cancer Prevention, 2011, 20, S20-S25. | 0.6 | 9 |
| 62 | Lung cancer risks, beliefs and healthcare access among the underprivileged. European Journal of Cancer Prevention, 2015, 24, S82-S86. | 0.6 | 9 |
| 63 | Cancer screening in France. European Journal of Cancer Prevention, 2015, 24, S68-S72. | 0.6 | 9 |
| 64 | Links between personality, time perspective, and intention to practice physical activity during cancer treatment: an exploratory study. Psycho-Oncology, 2017, 26, 531-536. | 1.0 | 9 |
| 65 | Awareness and Misconceptions of Breast Cancer Risk Factors Among Laypersons and Physicians. Current Oncology Reports, 2018, 20, 15. | 1.8 | 9 |
| 66 | Decline in Cancer Screening in Vulnerable Populations? Results of the EDIFICE Surveys. Current Oncology Reports, 2018, 20, 17. | 1.8 | 9 |
| 67 | Breast cancer guidelines-Physicians' intentions and behaviors. International Journal of Cancer, 2006, 120, 1136-1140. | 2.3 | 8 |
| 68 | Genetic Testing for Familial Cancer. Public Health Genomics, 2008, 11, 63-67. | 0.6 | 8 |
| 69 | Mammography utilization in women aged 40â€“49 years. European Journal of Cancer Prevention, 2011, 20, S16-S19. | 0.6 | 8 |
| 70 | Breast cancer screening controversy. European Journal of Cancer Prevention, 2015, 24, S73-S76. | 0.6 | 8 |
| 71 | Socioeconomic deprivation is associated with decreased survival in patients with acute myeloid leukemia. Cancer Epidemiology, 2020, 66, 101699. | 0.8 | 8 |
| 72 | Social stratification, risk factor prevalence and cancer screening attendance. European Journal of Cancer Prevention, 2015, 24, S77-S81. | 0.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Acceptability of cancer chemoprevention trials: impact of the design. International Journal of Medical Sciences, 2008, 5, 244-247. | 1.1 | 8 |
| 74 | Cancer prone persons. A randomized screening trial based on colonoscopy: background, design and recruitment. Familial Cancer, 2001, 1, 175-179. | 0.9 | 7 |
| 75 | Familial hematological malignancies: new IDH2 mutation. Annals of Hematology, 2016, 95, 1943-1947. | 0.8 | 7 |
| 76 | Cancer survivors: familial risk perception and management advice given to their relatives. Familial Cancer, 2011, 10, 147-155. | 0.9 | 6 |
| 77 | GATA2 gene analysis in several forms of hematological malignancies including familial aggregations. Annals of Hematology, 2017, 96, 1635-1639. | 0.8 | 6 |
| 78 | Abstract 4447: In search of the ideal cancer screening test. , 2012, , . | | 6 |
| 79 | Marker segregation information in breast/ovarian cancer genetic counseling: Is it still useful?. , 1998, 79, 175-183. | | 5 |
| 80 | Breast cancer and breastfeeding. Lancet, The, 2003, 361, 176-177. | 6.3 | 5 |
| 81 | Behavioral and Economic Impact of a Familial History of Cancers. Familial Cancer, 2005, 4, 307-311. | 0.9 | 5 |
| 82 | Cancer screening. European Journal of Cancer Prevention, 2011, 20, S42-S44. | 0.6 | 5 |
| 83 | Impact of awareness of cancer among acquaintances on cancer screening attendance. European Journal of Cancer Prevention, 2011, 20, S36-S38. | 0.6 | 5 |
| 84 | Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study. European Journal of Human Genetics, 2012, 20, 981-983. | 1.4 | 5 |
| 85 | Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey. Current Oncology Reports, 2018, 20, 14. | 1.8 | 5 |
| 86 | Screening for prostate cancer. European Journal of Cancer Prevention, 2011, 20, S33-S35. | 0.6 | 4 |
| 87 | Histoprognostic Grade in Hereditary Breast Cancer: Is Inheritance Linked to BRCA1 a Bad Prognostic Factor?. , 1996, , 11-18. | | 3 |
| 88 | Management of women at high genetic risk of ovarian cancer. Lancet, The, 1999, 354, 1648. | 6.3 | 3 |
| 89 | Uptake of breast cancer screening in women aged over 75years. European Journal of Cancer Prevention, 2011, 20, S13-S15. | 0.6 | 3 |
| 90 | Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies. Annals of Hematology, 2016, 95, 1043-1050. | 0.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers. BMC Medical Research Methodology, 2021, 21, 155. | 1.4 | 3 |
| 92 | Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation. Breast Cancer Research, 2021, 23, 79. | 2.2 | 3 |
| 93 | Decision analysis in patients' care. Lancet, The, 2001, 358, 2173. | 6.3 | 2 |
| 94 | Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer. JCO Precision Oncology, 2018, 2, 1-8. | 1.5 | 2 |
| 95 | Vulnerable populations and overconfidence in cancer screening.. Journal of Clinical Oncology, 2014, 32, 1574-1574. | 0.8 | 2 |
| 96 | Tamoxifen's effect in women with breast cancer. Lancet, The, 2001, 357, 1291. | 6.3 | 1 |
| 97 | Hereditary cancer gene hunting. A phase of declining success?. Medical Hypotheses, 2007, 69, 690-692. | 0.8 | 1 |
| 98 | CYP2D6 and Ockham's Razor. Journal of Clinical Oncology, 2008, 26, 686-687. | 0.8 | 1 |
| 99 | Increasing Coverage Rates for Mammographic Screening in France in Older Women--16â€ƒYears of Follow-Up. Breast Journal, 2011, 17, 686-688. | 0.4 | 1 |
| 100 | Knowledge-Based Cancer Control. Current Oncology Reports, 2018, 20, 19. | 1.8 | 1 |
| 101 | Cancer screening. European Journal of Cancer Prevention, 2015, 24, S65-S67. | 0.6 | 1 |
| 102 | Breast cancer screening controversy: Impact on other cancer screening programs.. Journal of Clinical Oncology, 2014, 32, e12507-e12507. | 0.8 | 1 |
| 103 | Phenocopies: actual risk or self-fulfilling prophecy?. Journal of Medical Genetics, 2007, 44, e87; author reply e88. | 1.5 | 1 |
| 104 | Les nouveaux consommateurs du gÃ©nome. Biofutur, 2000, 2000, 96-98. | 0.0 | 0 |
| 105 | Breast cancer surveillance is less effective for high risk women. Evidence-Based Healthcare and Public Health, 2001, 5, 111-112. | 0.0 | 0 |
| 106 | Re: Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. Journal of the National Cancer Institute, 2009, 101, 277-277. | 3.0 | 0 |
| 107 | Re: Performance of First Mammography Examination in Women Younger Than 40 Years. Journal of the National Cancer Institute, 2010, 102, 1742-1742. | 3.0 | 0 |
| 108 | Angelina and Brad effect. Familial Cancer, 2016, 15, 541-542. | 0.9 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Mammographie : on dÃ©pisteâ€¦ on ne dÃ©piste pasâ€¦ on dÃ©pisteÂ?. Medecine/Sciences, 2002, 18, 814-816 | 0.0 | 0 |
| 110 | Genetic Risk Assessment and BRCA Mutation Testing. Annals of Internal Medicine, 2006, 144, 376. | 2.0 | 0 |